Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-23-015839
Filing Date
2023-06-16
Accepted
2023-06-16 20:07:01
Documents
1
Period of Report
2023-06-14

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3976
  Complete submission text file 0000899243-23-015839.txt   5431
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Issuer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 3 FORBES ROAD LEXINGTON MA 02421
Business Address
Baldoni John (Reporting) CIK: 0001851248 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40908 | Film No.: 231022988